Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
United Therapeutic (UTHR)
United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1040 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com P: 301-608-9292 F: 301-608-9291

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 11,293,126
Enterprise Value, $K 11,131,926
Shares Outstanding, K 46,994
Annual Sales, $ 1,936 M
Annual Net Income, $ 727,300 K
Last Quarter Sales, $ 609,400 K
Last Quarter Net Income, $ 267,600 K
EBIT, $ 1,100 M
EBITDA, $ 1,152 M
60-Month Beta 0.57
% of Insider Shareholders 12.50%
% of Institutional Shareholders 94.08%
Float, K 41,120
% Float 87.50%
Short Volume Ratio 0.58

Growth:

1-Year Return -12.21%
3-Year Return 73.26%
5-Year Return 122.74%
5-Year Revenue Growth 12.23%
5-Year Earnings Growth 37.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 5.38 on 11/01/23
Next Earnings Date N/A
Earnings Per Share ttm 18.15
EPS Growth vs. Prev Qtr 2.67%
EPS Growth vs. Prev Year 9.57%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 13.22
Price/Earnings forward 12.39
Price/Earnings to Growth N/A
Return-on-Equity % 17.10%
Return-on-Assets % 13.79%
Profit Margin % 37.56%
Net Margin % 20.32
Debt/Equity 0.15
Price/Sales 5.82
Price/Cash Flow 14.09
Price/Book 1.98
Book Value/Share 121.56
Interest Coverage 30.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar